Background: The authors aimed to conduct an extensive literature review and consensus meeting to identify unmet needs in ulcerative colitis (UC) and ways to overcome them. UC is a relapsing and remitting inflammatory bowel disease with varied, and changing, incidence rates worldwide. UC has an unpredictable disease course and is associated with a high health economic burden. During 2016 and 2017, a panel of experts was convened to identify, discuss and address areas of unmet need in UC. Methods: PubMed and Cochrane Library databases were searched for relevant articles describing studies performed in patients with UC. These findings were used to generate a set of statements relating to unmet needs in UC. Consensus on these statements was then sought from a panel of 9 expert gastroenterologists using a modified Delphi review process that consisted of anonymous surveys followed by live meetings. Results: In 2 literature reviews, over 5,000 unique records were identified and a total of 138 articles were fully reviewed. These were used to consider 26 areas of unmet need, which were explored in 2 face-to-face meetings, in which the statements were debated and amended, resulting in consensus on 30 final statements. The unmet needs identified were categorised into 7 areas: impact of UC on patients’ daily life; importance of early diagnosis and treatment; drawbacks of existing treatments; urgent need for new treatments; and disease-, practice- or patient-focused unmet needs. Conclusions: These expert group meetings found a number of areas of unmet needs in UC, which is an important first step in tackling them in the future. Future research and development should be focused in these areas for the management of patients with UC.

Keywords:
Consensus panel, Delphi process, Systematic literature review, Ulcerative colitis, Unmet needs
1.
Magro F, Gionchetti P, Eliakim R, et al: Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 2017; 11: 649–670.
2.
Collins P, Rhodes J: Ulcerative colitis: diagnosis and management. BMJ 2006; 333: 340–343.
3.
Hoivik ML, Moum B, Solberg IC, Cvancarova M, Hoie O, Vatn MH, Bernklev T; IBSEN Study Group: Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN Study. Inflamm Bowel Dis 2012; 18: 1540–1549.
4.
Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group: Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 2015; 148: 1035–1058.
5.
Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; European Crohn’s and Colitis Organisation [ECCO]: Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 2017; 11: 769–784.
6.
Danese S, Colombel JF, Peyrin-Biroulet L, Rutgeerts P, Reinisch W: Review article: the role of anti-TNF in the management of ulcerative colitis – past, present and future. Aliment Pharmacol Ther 2013; 37: 855–866.
7.
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–2476.
8.
Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB: Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257–265.
9.
Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P; PURSUIT-SC Study Group: Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85–95.
10.
Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P; PURSUIT-Maintenance Study Group: Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 96–109.
11.
Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S, Rutgeerts P: Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392–400.
12.
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699–710.
13.
Tulchinsky H, Dotan I, Halpern Z, Klausner JM, Rabau M: A longitudinal study of quality of life and functional outcome of patients with ulcerative colitis after proctocolectomy with ileal pouch-anal anastomosis. Dis Colon Rectum 2010; 53: 866–873.
14.
Hashavia E, Dotan I, Rabau M, Klausner JM, Halpern Z, Tulchinsky H: Risk factors for chronic pouchitis after ileal pouch-anal anastomosis: a prospective cohort study. Colorectal Dis 2012; 14: 1365–1371.
15.
Gordon JP, McEwan PC, Maguire A, Sugrue DM, Puelles J: Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol 2015; 27: 804–812.
16.
Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG: Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018; 390: 2769–2778.
17.
Kaplan GG: The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol 2015; 12: 720–727.
18.
Feuerstein JD, Cheifetz AS: Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc 2014; 89: 1553–1563.
19.
Lee JC, Lyons PA, McKinney EF, Sowerby JM, Carr EJ, Bredin F, Rickman HM, Ratlamwala H, Hatton A, Rayner TF, Parkes M, Smith KG: Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 2011; 121: 4170–4179.
20.
Bossuyt P, Baert F, Coenegrachts JL, De Vos M, Dewit O, Ferrante M, Fontaine F, Mana F, Vandervoort J, Moreels T: Belgian IBD research and development group: evaluation of step up therapy in patients with early ulcerative colitis: a prospective cohort study. Poster P347 presented at ECCO 2017.
21.
Linstone HA, Murray T (eds): The Delphi Method. Techniques and Applications. ­Boston, Addison-Wesley, 1975.
22.
Rowe G, Wright G: The Delphi technique: past, present, and future prospects – introduction to the special issue. Technol Forecast Soc Chang 2011; 78: 1487–1490.
23.
Bokemeyer B, Hardt J, Hüppe D, Prenzler A, Conrad S, Düffelmeyer M, Hartmann P, Hoffstadt M, Klugmann T, Schmidt C, Weismüller J, Mittendorf T, Raspe H: Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohns Colitis 2013; 7: 355–368.
24.
Kane SV: Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 577–585.
25.
LeBlanc K, Mosli MH, Parker CE, MacDonald JK: The impact of biological interventions for ulcerative colitis on health-related quality of life. Cochrane Database Syst Rev 2015; 9:CD008655.
26.
Büsch K, da Silva SA, Holton M, Rabacow FM, Khalili H, Ludvigsson JF: Sick leave and disability pension in inflammatory bowel disease: a systematic review. J Crohns Colitis 2014; 8: 1362–1377.
27.
Høivik ML, Moum B, Solberg IC, Henriksen M, Cvancarova M, Bernklev T; IBSEN Group: Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut 2013; 62: 368–375.
28.
Lopez A, Ford AC, Colombel JF, Reinisch W, Sandborn WJ, Peyrin-Biroulet L: Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: meta-analysis of placebo-controlled trials. Dig Liver Dis 2015; 47: 356–364.
29.
Filippi J, Allen PB, Hébuterne X, Peyrin-Biroulet L: Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? a systematic review. Curr Drug Targets 2011; 12: 1440–1447.
30.
Jeuring SF, Bours PH, Zeegers MP, Ambergen TW, van den Heuvel TR, Romberg-Camps MJ, van Bodegraven AA, Oostenbrug LE, Breukink SO, Stassen LP, Hameeteman WH, Masclee AA, Jonkers DM, Pierik MJ: Disease outcome of ulcerative colitis in an era of changing treatment strategies: results from the Dutch population-based IBDSL cohort. J Crohns Colitis 2015; 9: 837–845.
31.
Annese V, Duricova D, Gower-Rousseau C, Jess T, Langholz E: Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a focus paper by the epidemiology committee of ECCO. J Crohns Colitis 2016; 10: 216–225.
32.
Schreiber S, Panés J, Louis E, Holley D, Buch M, Paridaens K: Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. BMC Gastroenterol 2012; 12: 108.
33.
Schreiber S, Panés J, Louis E, Holley D, Buch M, Paridaens K: National differences in ulcerative colitis experience and management among patients from five European countries and Canada: an online survey. J Crohns Colitis 2013; 7: 497–509.
34.
Magro F, Portela F, Lago P, Deus J, Cotter J, Cremers I, Vieira A, Peixe P, Caldeira P, Lopes H, Gonçalves R, Reis J, Cravo M, Barros L, Ministro P, Lurdes Tavares M, Duarte A, Campos M, Carvalho L; Portuguese Study Group of IBD (GEDII); Association of Portuguese Patients with IBD (APDI): Inflammatory bowel disease: a patient’s and caregiver’s perspective. Dig Dis Sci 2009; 54: 2671–2679.
35.
Waterman M, Knight J, Dinani A, Xu W, Stempak JM, Croitoru K, Nguyen GC, Cohen Z, McLeod RS, Greenberg GR, Steinhart AH, Silverberg MS: Predictors of outcome in ulcerative colitis. Inflamm Bowel Dis 2015; 21: 2097–2105.
36.
Kent A, Keshav S: Managing intractable proctitis and the problematic pouch. Dig Dis 2014; 32: 427–437.
37.
Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R: Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780–787.
38.
Isaacs KL: How rapidly should remission be achieved? Dig Dis 2010; 28: 548–555.
39.
Sands BE: The risks and benefits of early immunosuppression and biological therapy. Dig Dis 2012; 30(suppl 3): 100–106.
40.
Lewis JD, Gelfand JM, Troxel AB, Forde KA, Newcomb C, Kim H, Margolis DJ, Strom BL: Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol 2008; 103: 1428–1435.
41.
Bernstein CN, Ng SC, Lakatos PL, Moum B, Loftus EV Jr; Epidemiology and Natural History Task Force of the International Organization of the Study of Inflammatory Bowel Disease: A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis 2013; 19: 2001–2010.
42.
van Bodegraven AA, Mulder C: Indications for 5-aminosalicylate in inflammatory bowel disease: Is the body of evidence complete? World J Gastroenterol 2006; 12: 6115–6123.
43.
Probert C: Steroids and 5-aminosalicylic acids in moderate ulcerative colitis: addressing the dilemma. Therap Adv Gastroenterol 2013; 6: 33–38.
44.
Loftus EV Jr, Davis KL, Wang CC, Dastani H, Luo A: Treatment patterns, complications, and disease relapse in a real-world population of patients with moderate-to-severe ulcerative colitis initiating immunomodulator therapy. Inflamm Bowel Dis 2014; 20: 1361–1367.
45.
Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Sociale O, Papa A, De Vitis I, Rapaccini GL, Guidi L: Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis 2013; 19: 1065–1072.
46.
Baki E, Zwickel P, Zawierucha A, Ehehalt R, Gotthardt D, Stremmel W, Gauss A: Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis. World J Gastroenterol 2015; 21: 3282–3290.
47.
Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK: Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2014; 39: 660–671.
48.
Allez M, Karmiris K, Louis E, Van Assche G, Ben-Horin S, Klein A, Van der Woude J, Baert F, Eliakim R, Katsanos K, Brynskov J, Steinwurz F, Danese S, Vermeire S, Teillaud JL, Lémann M, Chowers Y: Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355–366.
49.
Kawalec P, Mikrut A, Łopuch S: Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis. J Gastroenterol Hepatol 2014; 29: 1159–1170.
50.
Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG: The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017; 66: 839–851.
51.
Danese S, Vuitton L, Peyrin-Biroulet L: Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol 2015; 12: 537–545.
52.
Hodgkins P, Swinburn P, Solomon D, Yen L, Dewilde S, Lloyd A: Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment. Patient 2012; 5: 33–44.
53.
Bernal I, Domènech E, Garcia-Planella E, Marín L, Mañosa M, Navarro M, Cabré E, Gassull MA: Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006; 51: 2165–2169.
54.
Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC, Hood K, Probert CS: One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. Inflamm Bowel Dis 2012; 18: 1885–1893.
55.
Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L: Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis 2013; 19: 1528–1533.
56.
Engel MA, Neurath MF: New pathophysiological insights and modern treatment of IBD. J Gastroenterol 2010; 45: 571–583.
57.
Peyrin-Biroulet L, Van Assche G, Sturm A, Gisbert JP, Gaya DR, Bokemeyer B, Mantzaris GJ, Armuzzi A, Sebastian S, Lara N, Lynam M, Rojas-Farreras S, Fan T, Ding Q, Black CM, Kachroo S: Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: a real world-based study. Dig Liver Dis 2016; 48: 601–607.
58.
Vavricka SR, Bentele N, Scharl M, Rogler G, Zeitz J, Frei P, Straumann A, Binek J, Schoepfer AM, Fried M; Swiss IBDnet and Swiss IBD Cohort Study Group: Systematic assessment of factors influencing preferences of Crohn’s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis 2012; 18: 1523–1530.
59.
Buisson A, Seigne AL, D’huart MC, Bigard MA, Peyrin-Biroulet L: The extra burden of infliximab infusions in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2464–2467.
60.
Olivera P, Danese S, Peyrin-Biroulet L: Next generation of small molecules in inflammatory bowel disease. Gut 2017; 66: 199–209.
61.
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D’Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group: Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 1383–1395.
62.
Kiss LS, Lakatos PL: Natural history of ulcerative colitis: current knowledge. Curr Drug Targets 2011; 12: 1390–1395.
63.
Eriksson C, Rundquist S, Cao Y, Montgomery S, Halfvarson J: Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study. Gut 2018, Epub ahead of print.
64.
Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ: Ulcerative colitis. Lancet 2012; 380: 1606–1619.
65.
Hanauer SB: Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther 2008; 27(suppl 1): 15–21.
66.
Peyrin-Biroulet L: Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature. Am J Gastroenterol 2013; 108: 859–860.
67.
Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A: Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53: 1813–1816.
68.
Peyrin-Biroulet L, Bressenot A, Kampman W: Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol 2014; 12: 929–934.
69.
Pittet V, Maillard MH, Lauvergeon S, Timmer M, Michetti P, Froehlich F, Burnand B, Vader JP, Mottet C: Acceptance of inflammatory bowel disease treatment recommendations based on appropriateness ratings: do practicing gastroenterologists agree with experts? J Crohns Colitis 2015; 9: 132–139.
70.
Spiegel BM, Ho W, Esrailian E, Targan S, Higgins PD, Siegel CA, Dubinsky M, Melmed GY: Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol 2009; 7: 168–174.
71.
Florholmen J, Fries W: Candidate mucosal and surrogate biomarkers of inflammatory bowel disease in the era of new technology. Scand J Gastroenterol 2011; 46: 1407–1417.
72.
Rogler G, Biedermann L: Clinical utility of biomarkers in IBD. Curr Gastroenterol Rep 2015; 17: 26.
73.
Magro F, Lopes J, Borralho P, Lopes S, Coelho R, Cotter J, Castro FD, Sousa HT, Salgado M, Andrade P, Vieira AI, Figueiredo P, Caldeira P, Sousa A, Duarte MA, Ávila F, Silva J, Moleiro J, Mendes S, Giestas S, Ministro P, Sousa P, Gonçalves R, Gonçalves B, Oliveira A, Rosa I, Rodrigues M, Chagas C, Dias CC, Afonso J, Geboes K, Carneiro F; Portuguese IBD Study Group (GEDII): Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels. Gut 2018, Epub ahead of print.
74.
Magnusson MK, Strid H, Isaksson S, Bajor A, Lasson A, Ung KA, Öhman L: Cultured blood T-cell responses predict anti-TNF therapy response in patients with ulcerative colitis. Aliment Pharmacol Ther 2015; 41: 1149–1161.
75.
European Crohn’s and Colitis Organisation e-guide. https://www.ecco-ibd.eu/index.php/publications/ecco-guidelines-science/published-ecco-guidelines.html. (accessed July 2017)
76.
Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; European Crohn’s and Colitis Organisation [ECCO]: Third European evidence-based consensus on Diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 2017; 11: 769–784.
77.
Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group: Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the toronto consensus. Gastroenterology 2015; 148: 1035–1058.
78.
Bodger K, Ormerod C, Shackcloth D, Harrison M; IBD Control Collaborative: Development and validation of a rapid, generic measure of disease control from the patient’s perspective: the IBD-Control questionnaire. Gut 2014; 63: 1092–1102.
79.
Vasudevan A, Arachchi A, van Langenberg DR: Assessing patient satisfaction in inflammatory bowel disease using the QUOTE-IBD survey: a small step for clinicians, a potentially large step for improving quality of care. J Crohns Colitis 2013; 7:e367–e374.
80.
Bojic D, Bodger K, Travis S: Patient reported outcome measures (PROMs) in inflammatory bowel disease: new data. J Crohns Colitis 2017; 11(suppl 2):S576–S585.
81.
Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, D’Haens G, Sandborn WJ, Feagan BG, Levesque BG: Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther 2015; 42: 1200–1210.
82.
Nahon S, Lahmek P, Durance C, Olympie A, Lesgourgues B, Colombel JF, Gendre JP: Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2086–2091.
83.
Villoria A, García V, Dosal A, Moreno L, Montserrat A, Figuerola A, Horta D, Calvet X, Ramírez-Lázaro MJ: Fatigue in out-patients with inflammatory bowel disease: prevalence and predictive factors. PLoS One 2017; 12:e0181435.
84.
Rubin DT, Dubinsky MC, Panaccione R, Siegel CA, Binion DG, Kane SV, Hopper J: The impact of ulcerative colitis on patients’ lives compared to other chronic diseases: a patient survey. Dig Dis Sci 2010; 55: 1044–1052.
85.
Lönnfors S, Vermeire S, Greco M, Hommes D, Bell C, Avedano L: IBD and health-related quality of life – discovering the true impact. J Crohns Colitis 2014; 8: 1281–1286.
86.
Wilson B, Lonnfors S, Hommes DW, Vermeire V, Greco M, Bell C, Avedano L: A European Crohn’s and ulcerative colitis patient life IMPACT survey. Poster P406 presented at ECCO 2012.
87.
Kiebles JL, Doerfler B, Keefer L: Preliminary evidence supporting a framework of psychological adjustment to inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1685–1695.
88.
Sajadinejad MS, Asgari K, Molavi H, Kalantari M, Adibi P: Psychological issues in inflammatory bowel disease: an overview. Gastroenterol Res Pract 2012; 2012: 106502.
89.
van Assche G, Peyrin-Biroulet L, Sturm A, Gisbert JP, Gaya DR, Bokemeyer B, Mantzaris GJ, Armuzzi A, Sebastian S, Lara N, Lynam M, Rojas-Farreras S, Fan T, Ding Q, Black CM, Kachroo S: Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months – multicenter European cohort study. Dig Liver Dis 2016; 48: 592–600.
90.
Baars JE, Markus T, Kuipers EJ, van der Woude CJ: Patients’ preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study. Digestion 2010; 81: 113–119.
91.
Elkjaer M, Shuhaibar M, Burisch J, Bailey Y, Scherfig H, Laugesen B, Avnstrøm S, Langholz E, O’Morain C, Lynge E, Munkholm P: E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided ‘constant-care’ approach. Gut 2010; 59: 1652–1661.
92.
Rogler G, Biedermann L: Clinical utility of biomarkers in IBD. Curr Gastroenterol Rep 2015; 17: 26.
93.
Tanaka M, Kawakami A, Iwao Y, Fukushima T, Yamamoto-Mitani N: Coping strategies for possible flare-ups and their perceived effectiveness in patients with inflammatory bowel disease. Gastroenterol Nurs 2016; 39: 42–47.
94.
Boye B, Lundin KE, Jantschek G, Leganger S, Mokleby K, Tangen T, Jantschek I, Pripp AH, Wojniusz S, Dahlstroem A, Rivenes AC, Benninghoven D, Hausken T, Roseth A, Kunzendorf S, Wilhelmsen I, Sharpe M, Blomhoff S, Malt UF, Jahnsen J: INSPIRE Study: Does stress management improve the course of inflammatory bowel disease and disease-specific quality of life in distressed patients with ulcerative colitis or crohn’s disease? a randomized controlled trial. Inflamm Bowel Dis 2011; 17: 1863–1873.
95.
Gisbert JP, Linares PM, McNicholl AG, Maté J, Gomollón F: Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009; 30: 126–137.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.